Elevated neutrophil‑to‑lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S‑1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer

Gonda,Kenji; Shibata,Masahiko; Sato,Yu; Washio,Maria; Takeshita,Hiroyuki; Shigeta,Hirofumi; Ogura,Michikazu; Oka,Shinichi; Sakuramoto,Shinich

doi:10.3892/mco.2017.1438

Elevated neutrophil‑to‑lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S‑1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer

Authors:
- Kenji Gonda
- Masahiko Shibata
- Yu Sato
- Maria Washio
- Hiroyuki Takeshita
- Hirofumi Shigeta
- Michikazu Ogura
- Shinichi Oka
- Shinich Sakuramoto
View Affiliations

Affiliations: Department of Surgery, Japan Community Healthcare Organization, Nihonmatsu Hopsital, Nihonmatsu, Fukushima 964-8501, Japan, Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Surgery, Saitama Medical University International Medical Center, Hidaka, Saitama 350-1298, Japan
Published online on: October 4, 2017 https://doi.org/10.3892/mco.2017.1438
Pages: 1073-1078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer continues to be a major cause of morbidity and mortality worldwide. Recently, there has been a growing interest in the host inflammatory response and there is increasing evidence that the neutrophil to lymphocyte ratio (NLR), which is a useful marker of systemic inflammation, can be an effective prognostic indicator in various types of malignant diseases. A total of 110 patients with stage IV gastric cancer who received chemotherapy of S‑1 plus cisplatin were enrolled in this study. Eleven patients did not complete four cycles of the chemotherapy. The patients were divided into two groups with 3.0 of NLR. The percentage of patients with a partial response to chemotherapy was significantly higher in the group of patients with a lower NLR (<3) (19.1 vs. 38.5%, high vs. low NLR group, respectively; P<0.05). The percentage of patients with progressive disease was higher in the high vs. low NLR group (57.4 vs. 25.0%, respectively; P<0.05). NLR levels were significantly inversely correlated with serum levels of prealbumin (P<0.01) and retinol binding protein (P<0.05). NLR levels were also significantly correlated with c‑reactive protein levels (P<0.05), white blood cell count (P<0.05) and inversely with the stimulation index (a marker of cell‑mediated immune function; P<0.05). Overall survival was significantly longer in patients with a lower NLR (≤ 3.0) than in those with a higher NLR (>3.0). The present study demonstrated that the NLR is a useful marker for resistance to chemotherapy, malnutrition, systemic inflammation and immune suppression. Moreover, the NLR was demonstrated to be a strong prognostic indicator in these patients.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
4	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
5	Jaiswal M, LaRusso NF, Burgart LJ and Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 60:184–190. 2000.PubMed/NCBI
6	McMilan DC: The systemic inflammation-based Glasgow prognostic score: A decade of experience in patients with cancer. Cancer Treat Rev. 39:534–540. 2013. View Article : Google Scholar : PubMed/NCBI
7	Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F and Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tomita M, Shimizu T, Ayabe T, Yonei A and Onitsuka T: Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection of non-small lung cancer. Anticancer Res. 31:2995–2998. 2011.PubMed/NCBI
9	Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R and Mauri FA: Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 110:1930–1935. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu J, Yue D, Zhang B and Wang C: Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: Based on a large cohort study. PLoS One. 10:e01264962015. View Article : Google Scholar : PubMed/NCBI
11	Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K and Hirakawa K: The prognostic significance of a postoperative systemic inflammatory response in patients with colorectal cancer. World J Surg Oncol. 13:1942015. View Article : Google Scholar : PubMed/NCBI
12	Albayrak S, Zengin K, Tanik S, Atar M, Unal SH, Imamoglu MA and Gurdal M: Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? Kaohsiung J Med Sci. 32:327–333. 2016. View Article : Google Scholar : PubMed/NCBI
13	Dong YW, Shi YQ, He LW and Su PZ: Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: A meta-analysis. Onco Targets Ther. 9:3127–3134. 2016.PubMed/NCBI
14	Nakamura K, Nagasaka T, Nishida T, Haruma T, Ogawa C, Kusumoto T, Seki N and Hiramatsu Y: Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. Oncol Lett. 11:3975–3981. 2016.PubMed/NCBI
15	Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K and Torimura T: The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol. 5:83–88. 2016. View Article : Google Scholar : PubMed/NCBI
16	Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection of stage IIA colon cancer. Int J Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY and Kim YJ: Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol. 104:504–510. 2011. View Article : Google Scholar : PubMed/NCBI
18	Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, et al: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
19	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
20	McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
21	Zahorec R: Ratio of neutrophil to lymphocyte count-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 102:5–14. 2001.(In English, Slovak). PubMed/NCBI
22	Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
23	Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y and Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative foe advanced and recurrent gastrointestinal cancers. S-1 Gastrointestinal Cancer Study Group. Oncology. 57:202–210. 1999. View Article : Google Scholar : PubMed/NCBI
24	Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
25	Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 58:191–197. 2000. View Article : Google Scholar : PubMed/NCBI
26	Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
27	Shibata M and Gonda K: Cachexia, immunological participationIn: Horizons in Cancer Research. 58. Nova Science Publishers Inc; New York: 2015
28	Tisdale MJ: Biology of cachexia. J Natl Cancer Inst. 89:1763–1773. 1997. View Article : Google Scholar : PubMed/NCBI
29	Shibata M, Nezu T, Kanou H, Abe H, Takekawa M and Fukuzawa M: Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420. 2002. View Article : Google Scholar : PubMed/NCBI
30	Shibata M, Nagata Y, Kimura T, Kanou H, Nezu T, Takekawa M and Fukuzawa M: Elevated serum concentration of interleukin-1 receptor antagonist (IL-1ra) is correlated to interleukin-6 and to hypoalbuminemia in cachectic patients with colorectal cancer. Int J Clin Oncol. 5:116–120. 2000. View Article : Google Scholar
31	Shibata M and Takekawa M: Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology. 56:54–58. 1999. View Article : Google Scholar : PubMed/NCBI
32	Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H and Takenoshita S: Circulating myeloid-derived suppressor cells are increased and correlated to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep. 28:453–458. 2012. View Article : Google Scholar : PubMed/NCBI
33	Nakamura I, Shibata M, Gonda K, Yazawa T, Shimura T, Anazaa T, Suzuki S, Sakurai K, Koyama Y, Ohto H, et al: Serum levels of vascular endothelial growth factor are increased and correlated with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patient with cancer of the digestive system. Oncol Lett. 5:1682–1686. 2013.PubMed/NCBI
34	Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T and Kono K: Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
35	Yoshimoto Y, Kono K and Suzuki Y: Anti-tumor immune responses induced by radiotherapy: A review. Fukushima J Med Sci. 61:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
36	Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Pedro Bravo-San JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al: Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 6:5882015. View Article : Google Scholar : PubMed/NCBI
37	Wang RF and Wang HY: Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 27:11–37. 2017. View Article : Google Scholar : PubMed/NCBI